Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
Type:
Grant
Filed:
April 8, 2022
Date of Patent:
December 24, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
Abstract: A method or system for training a convolutional neural network (CNN) for medical imaging analysis. The system pre-trains the CNN's encoder using a dataset of unlabeled 3D medical images. Each 3D image includes an annotated slice delineating a boundary of a lesion and multiple non-annotated 2D slices above and below the annotated slice. The system then fine-tunes the pre-trained encoder using an annotated 2D image dataset. The annotated 2D image dataset includes multiple 2D slices of lesions, each including an annotation that delineates a boundary of a corresponding lesion.
Abstract: A pigment mixture comprising at least two or three interference pigments of different interference colours selected from the colours red, green and blue, suitable for use in paints, coatings, printing inks, security printing inks, plastics, ceramic materials, glasses and in the preparation of pigment preparations, dry preparations and in particular cosmetic formulations.
Type:
Grant
Filed:
January 23, 2019
Date of Patent:
December 24, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Christoph Schmidt, Carsten Plueg, Uwe Lenz, Sabine Schoen
Abstract: Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
December 24, 2024
Assignee:
Merck Patent GmbH
Inventors:
Giorgio Massimini, Ilhan Celik, Josef Straub, Rolf Bruns, Rita Laeufle
Abstract: The invention relates to compounds that can be used in an organic electronic device as an active compound, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising same.
Abstract: In some examples, an injector includes a base, a housing movable relative to the base, a needle unit disposed within the base, the needle unit comprising at least one piercing needle configured to pierce a pierceable membrane of a drug product container, and at least one microneedle disposed on an opposite side of the at least one piercing needle, and a driving mechanism configured and arranged to drive at least one of the drug product container and the needle unit toward another of the drug product container and the needle unit.
Type:
Application
Filed:
November 1, 2022
Publication date:
December 19, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Daniel A. Bonanno, John B. Cline, Eduardo Cristofolli, Cassie Megna, Wail A. Rasheed, Ophelia L. Wells
Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
Type:
Grant
Filed:
May 13, 2024
Date of Patent:
December 17, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, Jr., Rebecca Nofsinger, Melanie J. Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
Abstract: The present invention relates to a pharmaceutical formulation of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof, as well as a method of making same, as well as medical uses thereof.
Type:
Application
Filed:
August 21, 2024
Publication date:
December 12, 2024
Applicant:
Merck Patent GmbH
Inventors:
Simon Geissler, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
Abstract: The present invention relates to a method for preparing an optical metal oxide layer, to a formulation for preparing an optical metal oxide layer and to an optical device comprising an optical metal oxide layer. The optical metal oxide layers are particularly suitable for optical applications and may be used in optical devices such as, for example, in diffractive gratings for augmented reality (AR) and/or virtual reality (VR) devices.
Type:
Application
Filed:
October 4, 2022
Publication date:
December 12, 2024
Applicant:
MERCK PATENT GMBH
Inventors:
Oliver DOLL, Hagai ARBELL, Henning SEIM, Oleg CHASHCHIKHIN
Abstract: The present disclosure provides, among other things, a vaccine composition that includes a squalene nanoemulsion (SNE) adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.
Type:
Application
Filed:
June 6, 2024
Publication date:
December 12, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Patrick L. Ahl, William J. Smith, Randal J. Soukup, Nicole Lea Sullivan, John Gaspar, Julie M. Skinner
Abstract: The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Type:
Application
Filed:
October 10, 2022
Publication date:
December 12, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Abdellatif El Marrouni, Antonella Converso, Ashley Forster
Abstract: Reactive mesogens (RMs), mixtures and formulations comprising RMs, polymers obtained from such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices, like optical films for liquid crystal displays (LCDs).
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
December 10, 2024
Assignee:
Merck Patent GmbH
Inventors:
Jack Bradford, Kevin Adlem, Naomi Weare, Vicki Poole, Iain Gardiner
Abstract: The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.
Type:
Grant
Filed:
June 9, 2022
Date of Patent:
December 10, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Patrick McHugh, Michael Albert Winters, Janelle Konietzko
Abstract: A process is described for production of a molecular layer on a substrate using atomic layer deposition (ALD) techniques, for use in electronic components, in particular, in memory elements of the ReRAM type. Additionally, compounds for production of the molecular layer are disclosed, as well as memory elements containing the molecular layer.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
December 10, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Peer Kirsch, Sebastian Resch, Henning Seim, Jacob Woodruff, Charith Nanayakkara
Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
Abstract: A liquid-crystal (LC) medium based on a mixture of polar compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the vertically aligned mode, to an LC display of the vertically aligned mode containing the LC medium, especially an energy-saving LC display and a process of manufacturing the LC display.
Type:
Grant
Filed:
June 1, 2023
Date of Patent:
December 10, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Harald Hirschmann, Sabine Schoen, Philipp Wucher
Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.
Inventors:
John Y. L. Chung, Tetsuji Itoh, Jungchul Kim, Jacob Henry Waldman, Debra J. Wallace, Andrew Wood, Feng Xu, Andrew Gibson, Jeremy Peter Scott
Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Type:
Application
Filed:
September 26, 2022
Publication date:
December 5, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Luis Torres, Xin Yan
Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
Type:
Application
Filed:
August 9, 2024
Publication date:
December 5, 2024
Applicant:
MERCK & CIE
Inventors:
Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
Type:
Application
Filed:
August 22, 2024
Publication date:
December 5, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski